1. Kahn, RSKeefe, RS (2013) Schizophrenia is a cognitive illness: time for a change in focus. JAMA psychiatry 70, 1107–1112.
2. Green, MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153, 321–330.
3. Howes, ODMurray, RM (2014) Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet (London, England) 383, 1677–1687.
4. Kroken, RA, Loberg, EM, Dronen, T, Gruner, R, Hugdahl, K, Kompus, K, Skrede, SJohnsen, E (2014) A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. Front Psychiatry 5, 11.
5. Heaton, RK, Gladsjo, JA, Palmer, BW, Kuck, J, Marcotte, TDJeste, DV (2001) Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58, 24–32.
6. Rodriguez-Sanchez, JM, Ayesa-Arriola, R, Perez-Iglesias, R, Perianez, JA, Martinez-Garcia, O, Gomez-Ruiz, E, Tabares-Seisdedos, RCrespo-Facorro, B (2013) Course of cognitive deficits in first episode of non-affective psychosis: a 3-year follow-up study. Schizophr Res 150, 121–128.
7. Ito, S, Nemoto, T, Tsujino, N, Ohmuro, N, Matsumoto, K, Matsuoka, H, Tanaka, K, Nishiyama, S, Brunel, L, Suzuki, M, Kinoshita, H, Ozawa, H, Fujita, H, Shimodera, S, Kishimoto, T, Matsumoto, K, Hasegawa, TMizuno, M (2015) Differential impacts of duration of untreated psychosis (DUP) on cognitive function in first-episode schizophrenia according to mode of onset. Eur Psychiatry 30, 995–1001.
8. Johnsen, E, Jorgensen, HA, Kroken, RALoberg, EM (2013) Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial. Eur Psychiatry 28, 174–184.
9. Rapado-Castro, M, Dodd, S, Bush, AI, Malhi, GS, Skvarc, DR, On, ZX, Berk, MDean, OM (2016) Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med 47, 1–11.
10. Martinez-Cengotitabengoa, M, Mico, JA, Arango, C, Castro-Fornieles, J, Graell, M, Paya, B, Leza, JC, Zorrilla, I, Parellada, M, Lopez, MP, Baeza, I, Moreno, C, Rapado-Castro, MGonzalez-Pinto, A (2014) Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. Schizophr Res 156, 23–29.
11. Johnsen, E, Fathian, F, Kroken, RA, Steen, VM, Jorgensen, HA, Gjestad, RLoberg, EM (2016) The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry 16, 60.
12. Anda, L, Bronnick, KS, Johnsen, E, Kroken, RA, Jorgensen, HLoberg, EM (2016) The course of neurocognitive changes in acute psychosis: relation to symptomatic improvement. PloS One 11, e0167390.
13. Lee, WHLee, WK (2017) Cognitive rehabilitation for patients with schizophrenia in Korea. Asian J Psychiatr 25, 109–117.
14. Best, MWBowie, CR (2017) A review of cognitive remediation approaches for schizophrenia: from top-down to bottom-up, brain training to psychotherapy. Expert Rev Neurother 17, 713–723.
15. Turkington, DMorrison, AP (2012) Cognitive therapy for negative symptoms of schizophrenia. Arch Gen Psychiatry 69, 119–120.
16. Davidson, M, Galderisi, S, Weiser, M, Werbeloff, N, Fleischhacker, WW, Keefe, RS, Boter, H, Keet, IP, Prelipceanu, D, Rybakowski, JK, Libiger, J, Hummer, M, Dollfus, S, Lopez-Ibor, JJ, Hranov, LG, Gaebel, W, Peuskens, J, Lindefors, N, Riecher-Rossler, AKahn, RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166, 675–682.
17. Nielsen, RE, Levander, S, Kjaersdam Telleus, G, Jensen, SO, Ostergaard Christensen, TLeucht, S (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131, 185–196.
18. Dickerson, F, Stallings, C, Origoni, A, Vaughan, C, Khushalani, SYolken, R (2013) Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 150, 456–459.
19. Khandaker, GMDantzer, R (2016) Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology 233, 1559–1573.
20. Fischer, EKDrago, A (2017) A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. J Neural Trans 124, 765–774.
21. Khandaker, GM, Cousins, L, Deakin, J, Lennox, BR, Yolken, RJones, PB (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2, 258–270.
22. Stefansson, H, Ophoff, RASteinberg, S (2009) Common variants conferring risk of schizophrenia. Nature 460.
23. Miller, BJGoldsmith, DR (2017) Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions. Neuropsychopharmacology 42, 299–317.
24. Ribeiro-Santos, A, Lucio Teixeira, ASalgado, JV (2014) Evidence for an immune role on cognition in schizophrenia: a systematic review. Curr Neuropharmacol 12, 273–280.
25. Bulzacka, E, Boyer, L, Schurhoff, F, Godin, O, Berna, F, Brunel, L, Andrianarisoa, M, Aouizerate, B, Capdevielle, D, Chereau-Boudet, I, Chesnoy-Servanin, G, Danion, JM, Dubertret, C, Dubreucq, J, Faget, C, Gabayet, F, Le Gloahec, T, Llorca, PM, Mallet, J, Misdrahi, D, Rey, R, Richieri, R, Passerieux, C, Roux, P, Yazbek, H, Leboyer, MFond, G (2016) Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull 42, 1290–1302.
26. Kahn, RSSommer, IE (2015) The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry 20, 84–97.
27. Najjar, SPearlman, DM (2015) Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 161, 102–112.
28. Deodhar, SD (1989) C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 56, 126–130.
29. Horsdal, HT, Kohler-Forsberg, O, Benros, MEGasse, C (2017) C-reactive protein and white blood cell levels in schizophrenia, bipolar disorders and depression - associations with mortality and psychiatric outcomes: a population-based study. Eur Psychiatry 44, 164–172.
30. Fan, X, Pristach, C, Liu, EY, Freudenreich, O, Henderson, DCGoff, DC (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatr Res 149, 267–271.
31. Dickerson, F, Stallings, C, Origoni, A, Vaughan, C, Khushalani, S, Yang, SYolken, R (2013) C-reactive protein is elevated in schizophrenia. Schizophr Res 143, 198–202.
32. Inoshita, M, Numata, S, Tajima, A, Kinoshita, M, Umehara, H, Nakataki, M, Ikeda, M, Maruyama, S, Yamamori, H, Kanazawa, T, Shimodera, S, Hashimoto, R, Imoto, I, Yoneda, H, Iwata, NOhmori, T (2016) A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep 6, 26105.
33. Fernandes, BS, Steiner, J, Bernstein, HG, Dodd, S, Pasco, JA, Dean, OM, Nardin, P, Goncalves, CABerk, M (2016) C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21, 554–564.
34. Wium-Andersen, MK, Orsted, DDNordestgaard, BG (2014) Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study. Schizophr Bulletin 40, 1117–1127.
35. Miller, BJ, Culpepper, NRapaport, MH (2014) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7, 223–230.
36. Dickerson, F, Stallings, C, Origoni, A, Boronow, JYolken, R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93, 261–265.
37. Dickerson, F, Stallings, C, Origoni, A, Vaughan, C, Khushalani, SYolken, R (2012) Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr Res 134, 83–88.
38. Johnsen, E, Kroken, RA, Wentzel-Larsen, TJorgensen, HA (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10, 26.
39. Kay, SR, Fiszbein, AOpler, LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13, 261–276.
40. Robinson, DG, Woerner, MG, Alvir, JM, Geisler, S, Koreen, A, Sheitman, B, Chakos, M, Mayerhoff, D, Bilder, R, Goldman, RLieberman, JA (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156, 544–549.
41. Addington, D, Addington, JSchissel, B (1990) A depression rating scale for schizophrenics. Schizophr Res 3, 247–251.
42. Drake, RE, Rosenberg, SDMueser, KT (1996) Assessing substance use disorder in persons with severe mental illness. New Dir Ment Health Serv 70, 3–17.
43. Guy, W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville,MD: Department of Health, Education, and Welfare.
44. Pedersen, GKarterud, S (2012) The symptom and function dimensions of the Global Assessment of Functioning (GAF) scale. Compr Psychiatry 53, 292–298.
45. Beglinger, LJ, Gaydos, B, Tangphao-Daniels, O, Duff, K, Kareken, DA, Crawford, J, Fastenau, PSSiemers, ER (2005) Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 20, 517–529.
46. Gold, JM, Queern, C, Iannone, VNBuchanan, RW (1999) Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 156, 1944–1950.
47. Wilk, CM, Gold, JM, Bartko, JJ, Dickerson, F, Fenton, WS, Knable, M, Randolph, CBuchanan, RW (2002) Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. Am J Psychiatry 159, 838–844.
48. Goldberg, TE, Keefe, RS, Goldman, RS, Robinson, DGHarvey, PD (2010) Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35, 1053–1062.
49. Goldberg, TE, Goldman, RS, Burdick, KE, Malhotra, AK, Lencz, T, Patel, RC, Woerner, MG, Schooler, NR, Kane, JMRobinson, DG Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64, 1115–1122.
50. Loberg, EM, Langeland, MJorgensen, HA (2006) Reliability and validity of a Norwegian translation of the repeatable battery for the assessment of neuropsychological status in patients with psychosis. Nevropsykologi 9, 36.
51. Muthén, LKMuthén, BO (2017) Mplus 8. Los Angeles, CA: Muthén & Muthén.
52. Wang, JWang, X (2012) Structural Equation Modeling: Applications Using Mplus Wiley Series in Probability and Statistics. West Sussex: Wiley, A John Wiley & Sons Ltd.
53. Newsom, JT (2015) Longitudinal Structural Equation Modeling. New York, NY: Routledge, Taylor & Francis Group.
54. Kline, RB (2010) Principles and Practice of Structural Equation Modeling, 3rd edn. New York, NY: The Guiford Press.
55. Bilder, RM, Lipschutz-Broch, L, Reiter, G, Geisler, SH, Mayerhoff, DILieberman, JA (1992) Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 18, 437–448.
56. Nopoulos, P, Flashman, L, Flaum, M, Arndt, SAndreasen, N (1994) Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res 14, 29–37.
57. Liberman, RPGreen, MF (1992) Whither cognitive-behavioral therapy for schizophrenia? Schizophr Bull 18, 27–35.
58. Tyson, PJ, Laws, KR, Roberts, KHMortimer, AM (2004) Stability of set-shifting and planning abilities in patients with schizophrenia. Psychiatr Res 129, 229–239.
59. Trampush, JW, Lencz, T, DeRosse, P, John, M, Gallego, JA, Petrides, G, Hassoun, Y, Zhang, JP, Addington, J, Kellner, CH, Tohen, M, Burdick, KE, Goldberg, TE, Kane, JM, Robinson, DGMalhotra, AK (2015) Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophr Bull 41, 1237–1247.
60. Mondelli, V, Pariante, CM, Navari, S, Aas, M, D’Albenzio, ADi Forti, M, Handley, R, Hepgul, N, Marques, TR, Taylor, H, Papadopoulos, AS, Aitchison, KJ, Murray, RMDazzan, P (2010) Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr Res 119, 75–78.
61. Buckley, PF, Pillai, A, Evans, D, Stirewalt, EMahadik, S (2007) Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 91, 1–5.
62. Martinez-Cengotitabengoa, M, Mac-Dowell, KS, Leza, JC, Mico, JA, Fernandez, MEchevarria, E, Sanjuan, J, Elorza, JGonzalez-Pinto, A (2012) Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 137, 66–72.
63. Micoulaud-Franchi, JA, Faugere, M, Boyer, L, Fond, G, Richieri, R, Faget, C, Cermolacce, M, Philip, P, Vion-Dury, JLancon, C (2015) Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophr Res 165, 94–96.
64. Misiak, B, Stanczykiewicz, B, Kotowicz, K, Rybakowski, JK, Samochowiec, JFrydecka, D (2018) Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res 192, 16–29.
65. Dickerson, F, Schroeder, J, Stallings, C, Origoni, A, Katsafanas, ESchwienfurth, LA, Savage, CL, Khushalani, SYolken, R (2014) A longitudinal study of cognitive functioning in schizophrenia: clinical and biological predictors. Schizophr Res 156, 248–253.
66. Wersching, H, Duning, T, Lohmann, H, Mohammadi, S, Stehling, C, Fobker, M, Conty, M, Minnerup, J, Ringelstein, EB, Berger, K, Deppe, MKnecht, S (2010) Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 74, 1022–1029.
67. Hsuchou, H, Kastin, AJ, Mishra, PKPan, W (2012) C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation. Cell Physiol Biochem 30, 1109–1119.
68. Bollen, KA (2002) Latent variables in psychology and the social sciences. Annu Rev Psychol 53, 605–634.
69. Bumb, JM, Enning, FLeweke, FM (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother 16, 1049–1067.
70. Muller, N, Riedel, M, Schwarz, MJEngel, RR (2005) Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 255, 149–151.
71. Rapado-Castro, M, Dodd, S, Bush, AI, Malhi, GS, Skvarc, DR, On, ZX, Berk, MDean, OM (2017) Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med 47, 866–876.
72. Levkovitz, Y, Mendlovich, S, Riwkes, S, Braw, Y, Levkovitch-Verbin, H, Gal, G, Fennig, S, Treves, IKron, S (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71, 138–149.
73. Chaudhry, IB, Hallak, J, Husain, N, Minhas, F, Stirling, J, Richardson, P, Dursun, S, Dunn, GDeakin, B (2012) Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26, 1185–1193.
74. Laan, W, Grobbee, DE, Selten, JP, Heijnen, CJ, Kahn, RSBurger, H (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71, 520–527.
75. Fenton, WS, Dickerson, F, Boronow, J, Hibbeln, JRKnable, M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158, 2071–2074.
76. Sommer, IE, van Westrhenen, R, Begemann, MJ, de Witte, LD, Leucht, SKahn, RS (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40, 181–191.